title: Treatment of margin positive basal cell carcinoma with vismodegib: case report and consideration of treatment options and their implications.
abstract: Historically, basal cell carcinomas (BCCs) that are neither surgically resectable nor candidates for radiation therapy have had few treatment options. The hedgehog pathway inhibitor, vismodegib, represents a new opportunity for the treatment of such patients. Vismodegib has approval from the United States Food and Drug Administration for treatment of metastatic BCC, locally advanced BCC recurring after surgery, and BCC that is not treatable via surgery or radiation. We present the case of a patient with a BCC infiltrating the spinal column that was neither possible to fully remove surgically nor a candidate for primary treatment with radiation. Treatment with vismodegib followed by adjuvant radiation therapy resulted in complete disease clearance. Vismodegib represents a promising treatment option for patients with surgically non-resectable BCCs that are not candidates for radiation therapy. Mechanism of action, benefits, and adverse events of vismodegib are reviewed, along with a brief discussion on newer options in the hedgehog inhibitor class.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Bayers
authors.forename: Daniel L
authors.initials: DL
authors.lastname: Kapp
authors.forename: Kenneth R
authors.initials: KR
authors.lastname: Beer
authors.forename: Benjamin
authors.initials: B
authors.lastname: Slavin
mesh_terms: D000368:Aged; D000813:Anilides / Q000009:adverse effects / Q000627:therapeutic use*; D001706:Biopsy; D002280:Basal Cell Carcinoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D017277:Drug Approval; D053823:Hedgehog Proteins / Q000037:antagonists & inhibitors; D006801:Humans; D008297:Male; D009361:Neoplasm Invasiveness; D011182:Postoperative Care; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D013125:Spinal Neoplasms / Q000473:pathology / Q000556:secondary / Q000601:surgery; D014057:Tomography, X-Ray Computed; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000813:Anilides; D053823:Hedgehog Proteins; C538724:HhAntag691; D011725:Pyridines